Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 4, 2003, Pages 605-609

  Ricci, Vito ^a   Piddock, Laura ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Antibiotic accumulation; Efflux pump inhibitors; Quinolones

Indexed keywords

CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CIPROFLOXACIN; CLINAFLOXACIN; GARENOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; UNCLASSIFIED DRUG; VANADATE SODIUM;

AGAR MEDIUM; ANAEROBIC GROWTH; ARTICLE; BACTERIAL GROWTH; BACTEROIDES FRAGILIS; BLOOD; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; DILUTION; DRUG ACCUMULATION; FLUOROMETRY; HYDROPHOBICITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR SIZE; NONHUMAN; STEADY STATE;

AZA COMPOUNDS; BACTEROIDES FRAGILIS; CIPROFLOXACIN; FLUOROQUINOLONES; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; QUINOLINES;

EID: 0141894014     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg418     Document Type: Article

References (30)

1. Oh, H., El Amin, N., Davies, T. et al. (2001). gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains. Antimicrobial Agents and Chemotherapy 45, 1977-81.
2. Miyamae, S., Nikaido, H., Tanaka, Y. et al. (1998). Active efflux of norfloxacin by Bacteroides fragilis. Antimicrobial Agents and Chemotherapy 42, 2119-21.
3. Brogan, O., Garnett, P. A. & Brown, R. (1989). Bacteroides fragilis resistant to metronidazole, clindamycin and cefoxitin. Journal of Antimicrobial Chemotherapy 23, 660-2.
4. Lamothe, F., Fijalkowski, C., Malouin, F. et al. (1986). Bacteroides fragilis resistant to both metronidazole and imipenem. Journal of Antimicrobial Chemotherapy 18, 642-3.
5. Rotimi, V. O., Duerden, B. I., Ede, V. et al. (1979). Metronidazole-resistant Bacteroides from untreated patient. Lancet 1, 833.
6. Snydman, D. R. & Cuchural, G. J. (1994). Susceptibility variations in Bacteroides fragilis: a national survey. Infectious Disease in Clinical Practice 3, S34-43.
7. Hoellman, D. B., Kelly, L. M., Michael, R. J. et al. (2001). Comparative anti-anaerobic activity of BMS 284756. Antimicrobial Agents and Chemotherapy 45, 589-92.
8. Milatovic, D., Schmitz, F-J., Brisse, S. et al. (2000). In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrobial Agents and Chemotherapy 44, 1102-7.
9. Snydman, D. R., Jacobus, N. V., McDermott, L. A. et al. (2000). Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of Bacteroides fragilis group: effect of the medium on test results. Antimicrobial Agents and Chemotherapy 44, 1710-12.
10. Davidson, R. J., De Azavedo, J., Bast, D. et al. (2000). The activity of BMS-284756, a novel des-(6)F-quinolone, against ciprofloxacin susceptible and nonsusceptible Streptococcus pneumoniae. In Program and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 2000. Abstract E1053, p. 175. American Society for Microbiology, Washington, DC, USA.
11. Fung-Tomc, J. C., Minassian, B., Kolek, B. et al. (2000). Antibacterial spectrum of a novel des-fluoro(6)quinolone, BMS-284756. Antimicrobial Agents and Chemotherapy 44, 3351-6.
12. Lawrence, L. E., Frosco, M., Ryan, B. M. et al. (2000). Bactericidal activity of BMS-284756, a novel des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations. In Program and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 2000. Abstract E1044, p.174. American Society for Microbiology, Washington, DC, USA.
13. Takahata, M., Mitsuyama, J., Yamashiro, Y. et al. (1999). In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrobial Agents and Chemotherapy 43, 1077-84.
14. Snydman, D. R., Jacobus, N. V., McDermott, L. A. et al. (2002). In vitro activities of newer quinolones against Bacteroides fragilis group organisms. Antimicrobial Agents and Chemotherapy 46, 3276-9.
15. Kirby, J. T., Mutnick, A. H., Jones, R. N. et al. (2002). Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagnostic Microbiology and Infectious Disease 43, 303-9.
16. Piddock, L. J. V. (1999). Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 58, Suppl. 2, 11-8.
17. Ricci, V. & Piddock, L. J. V. (2000). Accumulation of norfloxacin by Bacteroides fragilis. Antimicrobial Agents and Chemotherapy 44, 2361-6.
18. Miyamae, S., Ueda, O., Yoshimura, F. et al. (2001). A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrobial Agents and Chemotherapy 45, 3341-6.
19. Asuquo, A. E. & Piddock, L. J. V. (1993). Accumulation and killing kinetics of fifteen quinolones for Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 31, 865-80.
20. Kappel, E. M., Shakibaei, E., Bello, A. et al. (2002). Effects of the des-F(6)-quinolone garenoxacin (BMS-284756), in comparison to those of ciprofloxacin and ofloxacin, on joint cartilage in immature rats. Antimicrobial Agents and Chemotherapy 46, 3320-2.
21. Ashby, J., Piddock, L. J. V. & Wise, R. (1985). An investigation of the hydrophobicity of the quinolones. Journal of Antimicrobial Chemotherapy 16, 805-8.
22. Bazile, S., Moreau, N., Bouzard, D. et al. (1992). Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of fluoroquinolones. Antimicrobial Agents and Chemotherapy 36, 2622-7.
23. Piddock, L. J. V. & Johnson, M. M. (2002). Accumulation of ten fluoroquinolones by wildtype and efflux mutant Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 46, 813-20.
24. Poole, K. (2001). Multidrug resistance in Gram-negative bacteria. Current Opinions in Microbiology 4, 500-8.
25. Lomovskaya, O., Warren, M. S., Lee, A. et al. (2001). Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrobial Agents and Chemotherapy 45, 105-16.
26. Klyachko, K. A., Schuldiner, S. & Neyfakh, A. A. (1997). Mutations affecting substrate specificity of the Bacillus subtilis multidrug transporter Bmr. Journal of Bacteriology 179, 2189-93.
27. Aeschlimann, J. R., Dresser, L. D., Kaatz, G. W. et al. (1999). Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 43, 335-40.
28. Paulsen, I. T. & Lewis, K. (2001). Microbial multidrug efflux: introduction. Journal of Molecular Microbiology and Biotechnology 3, 143-4.
29. Drlica, K. & Zhao, X. (1997). DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiology and Molecular Biology Reviews 61, 377-92.
30. Mortimer, P. G. S. & Piddock L. J. V. (1991). Comparison for the methods used for measuring the accumulation of quinolones into Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 28, 639-53.